KITE Shares New Data at EHA 2024 Which Demonstrates Positive Patient Outcomes and Advances in Delivery of CAR T-Cell Therapy
May 14, 2024 – Clinical Trials, Pharmaceutical – CAR T-cell, EHA 2024, Gilead Sciences, Kite Pharma, multiple myeloma
- Analysis comparing real-world and clinical trial data shows Yescarta (Axicabtagene Ciloleucel) has higher manufacturing success rates and improved T-cell performance, respectively, in second-line vs third-line+ treatment of large B-cell lymphoma
- Encore oral presentation from the phase 1 study of Anitocabtagene autoleucel (anito-cel) in relapsed/refractory multiple myeloma (R/R MM); trial design for phase 3 iMMagine-3 pivotal study for R/R MM to be published as e-publication.
14 May 2024 — Stockley Park, UK — Kite, a Gilead Company, today announced 12 abstracts from its Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress,13-16 June in Madrid, Spain.
Four presentations will highlight real-world experience with Yescarta (axicabtagene ciloleucel), including manufacturing experience for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in second-line versus third-line treatment and beyond. The real-world manufacturing analysis investigated potential benefits of administering axicabtagene ciloleucel in earlier lines of therapy by assessing manufacturing success rate and product characteristics.
Analyses exploring outpatient administration of axicabtagene ciloleucel in R/R LBCL includes preliminary results of the Phase 2 ZUMA-24 study to evaluate the safety and efficacy of axicabtagene ciloleucel outpatient administration compared to previous in-hospital clinical trials and real-world evidence. A real-world analysis in collaboration with the Mayo Clinic on the use of axicabtagene ciloleucel and Tecartus (brexucabtagene autoleucel) assess safety trends and hospitalisation rates following treatment to further understand the feasibility of CAR T-cell therapy administration in the outpatient setting.
“Whether it’s continuing to evolve our industry-leading manufacturing capabilities or looking at different ways patients can obtain CAR T-cell therapy, such as in the outpatient setting, our goal is to improve patient outcomes and experience with our therapies,” said Ibrahim Elhoussieny, vice president, Medical Affairs, Kite. “This data will reflect our progress in helping CAR T reach more people with complex and hard-to-treat blood cancers.”
Kite and its multiple myeloma (MM) partner Arcellx will share the clinical trial design for the pivotal phase 3 iMMagine-3 trial, which will investigate the efficacy and safety of anitocabtagene autoleucel (anito-cel) versus standard of care in patients with R/R MM. In addition, Arcellx will highlight findings from the phase 1 study of anito-cel in R/R MM in an oral presentation. Anito-cel is an investigational BCMA CAR T – that utilises a novel binder known as the D-Domain. Its small size (8kDa) facilitates high T-cell transduction and expression, resulting in more CAR positive cells and more CARs expressed per T-cell.
About Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, US, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial production and commercial product manufacturing. Visit: www.kitepharma.com.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California, US. Gilead acquired Kite in 2017. Visit: www.gilead.com.
